Cost-effectiveness of rimegepant oral lyophilisate compared to best supportive care for the acute treatment of migraine in the UK.
Karissa M JohnstonLauren C PowellEvan PopoffGil J L'ItalienRobert PawinskiAideen AhernSam LargeThang TranAaron JenkinsPublished in: Journal of medical economics (2024)
This study highlights the economic value of rimegepant which was found to be cost-effective for the acute treatment of migraine in adults unsuitable for triptans.